Section Edited by Ignacio Melero, MD, PhD and Alexandra Snyder Charen, MD
This section focuses on the discovery, development and/or clinical significance of biomarkers for immunomodulatory anti-cancer treatments. This includes biomarkers for diagnostic, prognostic, predictive and pharmacodynamic purposes measured using diverse strategies including, but not limited to, genomic or gene expression,serological analyses, cell-based or single-cell studies, in situ/localized tissue-based protein imaging, high content/multiparametric molecular platforms and imaging studies conducted in model systems, retrospective collections and clinical trials.This section also welcomes studies reporting novel methods, technologies or computational approaches to interrogate the anti-tumor immune response that have the potential to advance the field. Manuscripts will be prioritized for peer review and publication on the basis of innovation/novelty of the biomarker-oriented research, adequate validation, clinical relevance and technological novelty. Special emphasis is assigned to: 1) Rigorous analytical validation of assays used (e.g. antibodies, mRNA probes, DNA sequences, molecular biosensors and modified reagents); 2) Reproducibility of findings in multiple populations/datasets/models; and 3) Use of appropriate statistics to account for cases stratification (e.g. cut-point selection), data overfitting and multiple hypothesis testing (e.g. adjustment of significance thresholds, P-values or other strategies to reduce type I error).
Prognostic model for unresectable hepatocellular carcinoma treated with dual PD-1 and angiogenesis blockade therapyZhiqiang Mo, Ling Lv, Qicong Mai, Qiao Li, Jian He, Tao Zhang, Jingwu Xu, Jiayan Fang, Ning Shi, Qing Gou, Xiaoming Chen, Jing Zhang, Wenhang Zhuang, Haosheng Jin
30 January 2024
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumabMara Serena Serafini, Stefano Cavalieri, Lisa Licitra, Federico Pistore, Deborah Lenoci, Silvana Canevari, Mario Airoldi, Maria Cossu Rocca, Primoz Strojan, Cvetka Grasic Kuhar, Marco Merlano, Federica Perrone, Andrea Vingiani, Nerina Denaro, Francesco PerriSee the full list of authors
30 January 2024
Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinomaFeng Zhang, Wenfeng Liu, Fansheng Meng, Qiuyu Jiang, Wenqing Tang, Zhiyong Liu, Xiahui Lin, Ruyi Xue, Si Zhang, Ling Dong
25 January 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4 naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanomaMagdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, Natalia Sigal, Li-Chun Cheng, William D Chronister, Shane A Evans, John Marsiglio, Berit Gibson, Umang Swami, Alyssa Erickson-Wayman, Jordan P McPherson, Yoko S Derose, Annaleah Larson Eliason, Carlos O MedinaSee the full list of authors
17 January 2024
CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical valueFrancesca Battaglin, Yasmine Baca, Joshua Millstein, Yan Yang, Joanne Xiu, Hiroyuki Arai, Jingyuan Wang, Fang-Shu Ou, Federico Innocenti, Shannon M Mumenthaler, Priya Jayachandran, Natsuko Kawanishi, Annika Lenz, Shivani Soni, Sandra AlgazeSee the full list of authors
11 January 2024
Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancerGulfem D Guler, Yuhong Ning, Ceyda Coruh, Giuliana P Mognol, Tierney Phillips, Maryam Nabiyouni, Kyle Hazen, Aaron Scott, Wayne Volkmuth, Samuel Levy
11 January 2024
TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapyShixiang Wang, Yi Xiong, Yihao Zhang, Haitao Wang, Minjun Chen, Jianfeng Li, Peng Luo, Yung-Hung Luo, Markus Hecht, Benjamin Frey, Udo Gaipl, Xuejun Li, Qi Zhao, Hu Ma, Jian-Guo Zhou
11 January 2024
Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective studyOlaf Penack, Thomas Luft, Christophe Peczynski, Axel Benner, Simona Sica, Mutlu Arat, Maija Itäla-Remes, Lucia López Corral, Nicolaas P M Schaap, Michal Karas, Ludek Raida, Thomas Schroeder, Peter Dreger, Elisabetta Metafuni, Tulay OzcelikSee the full list of authors
9 January 2024
Multiomics profiling reveals the benefits of gamma-delta (γδ) T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancerJunyi Li, Yuanjie Cao, Yancheng Liu, Lu Yu, Zhen Zhang, Xiaofeng Wang, Hui Bai, Yuhan Zhang, Shaochuan Liu, Miaomiao Gao, Chenglu Lu, Chen Li, Yong Guan, Zhen Tao, Zhiqiang WuSee the full list of authors
9 January 2024
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort studyDominik A Barth, Florian Moik, Sarah Steinlechner, Florian Posch, Marie-Christina Mayer, Amelie M Sandner, Franziska Berton, Verena Schlintl, Lukas Koch, Nikolaus John, Robert Wurm, Martin Pichler, Thomas Bauernhofer, Patrick Reimann, Christoph WohlkönigSee the full list of authors
14 December 2023